SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

• Status: Completed
• Trial end date: 2011-07-01

Summary

RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or combination chemotherapy, which uses different ways to stop tumor cells from dividing so they stop growing or die, may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chemotherapy, in treating patients who have malignant tumors that develop after organ transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborators: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
• Treatments: Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Etoposide phosphate; Interferon-alpha; Interferons; Liposomal doxorubicin; Methotrexate; Prednisone; Vincristine